Lories Rik J, Monteagudo Silvia
Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium.
Division of Rheumatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Rheumatol Ther. 2020 Jun;7(2):259-270. doi: 10.1007/s40744-020-00205-8. Epub 2020 Apr 10.
Osteoarthritis is the most common chronic joint disease affecting millions of people worldwide and a leading cause of pain and disability. Increasing incidence of obesity and aging of the population are two factors that suggest that the impact of osteoarthritis will further increase at the society level. Currently, there are no drugs available that can manage both structural damage to the joint or the associated pain. Increasing evidence supports the view that the Wnt signaling pathway plays an important role in this disease. The current concept, based on genetic and functional studies, indicates that tight regulation of Wnt signaling in cartilage is essential to keep the joint healthy. In this review, we discuss how this concept has evolved, provide insights into the regulation of Wnt signaling, in particular by Wnt modulators such as frizzled-related protein and DOT1-like histone lysine methyltransferase, and summarize preclinical evidence and molecular mechanisms of lorecivivint, the first Wnt antagonist in clinical development for osteoarthritis.
骨关节炎是全球影响数百万人的最常见慢性关节疾病,也是疼痛和残疾的主要原因。肥胖率上升和人口老龄化这两个因素表明,骨关节炎在社会层面的影响将进一步加剧。目前,尚无药物能够同时控制关节的结构损伤或相关疼痛。越来越多的证据支持Wnt信号通路在该疾病中起重要作用这一观点。基于基因和功能研究的当前概念表明,软骨中Wnt信号的严格调控对于维持关节健康至关重要。在本综述中,我们讨论了这一概念是如何演变的,深入探讨了Wnt信号的调控,特别是由卷曲相关蛋白和DOT1样组蛋白赖氨酸甲基转移酶等Wnt调节剂进行的调控,并总结了洛雷西维(lorecivivint)的临床前证据和分子机制,洛雷西维是首个进入骨关节炎临床开发阶段的Wnt拮抗剂。